Windtree Therapeutics, Inc. (WINT)
USD 1.0
(-0.45%)
USD 1.0
(-0.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 16.83 Million USD | 638.16% |
| 2022 | 2.28 Million USD | -21.19% |
| 2021 | 2.89 Million USD | -23.49% |
| 2020 | 3.78 Million USD | -40.11% |
| 2019 | 6.31 Million USD | -20.83% |
| 2018 | 7.97 Million USD | -46.84% |
| 2017 | 15 Million USD | -40.0% |
| 2016 | 25 Million USD | 0.0% |
| 2015 | 25 Million USD | 22.77% |
| 2014 | 20.36 Million USD | 10.1% |
| 2013 | 18.49 Million USD | 2702.42% |
| 2012 | 660 Thousand USD | -32.72% |
| 2011 | 981 Thousand USD | -8.4% |
| 2010 | 1.07 Million USD | -90.68% |
| 2009 | 11.48 Million USD | 13.41% |
| 2008 | 10.12 Million USD | -33.58% |
| 2007 | 15.24 Million USD | 12.05% |
| 2006 | 13.6 Million USD | 178.25% |
| 2005 | 4.89 Million USD | -35.5% |
| 2004 | 7.58 Million USD | 593.14% |
| 2003 | 1.09 Million USD | 145.84% |
| 2002 | 445 Thousand USD | 477.92% |
| 2001 | 77 Thousand USD | 60.42% |
| 2000 | 48 Thousand USD | 0.0% |
| 1999 | 48 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.48 Million USD | -91.18% |
| 2024 Q2 | 3.86 Million USD | 127.56% |
| 2023 FY | 16.83 Million USD | 638.16% |
| 2023 Q4 | 16.83 Million USD | 680.25% |
| 2023 Q3 | 2.15 Million USD | -13.58% |
| 2023 Q1 | 1.9 Million USD | -16.62% |
| 2023 Q2 | 2.49 Million USD | 31.3% |
| 2022 Q1 | 2.41 Million USD | -16.49% |
| 2022 Q3 | 2.77 Million USD | -15.28% |
| 2022 Q2 | 3.27 Million USD | 35.68% |
| 2022 Q4 | 2.28 Million USD | -17.9% |
| 2022 FY | 2.28 Million USD | -21.19% |
| 2021 Q1 | 5.23 Million USD | 38.56% |
| 2021 FY | 2.89 Million USD | -23.49% |
| 2021 Q3 | 3.2 Million USD | -16.22% |
| 2021 Q2 | 3.82 Million USD | -26.91% |
| 2021 Q4 | 2.89 Million USD | -9.82% |
| 2020 Q4 | 3.78 Million USD | -6.2% |
| 2020 Q1 | 5.9 Million USD | -6.46% |
| 2020 Q2 | 6.87 Million USD | 16.36% |
| 2020 Q3 | 4.03 Million USD | -41.33% |
| 2020 FY | 3.78 Million USD | -40.11% |
| 2019 Q1 | 9.45 Million USD | 18.51% |
| 2019 Q3 | 9.51 Million USD | -2.63% |
| 2019 FY | 6.31 Million USD | -20.83% |
| 2019 Q4 | 6.31 Million USD | -33.66% |
| 2019 Q2 | 9.77 Million USD | 3.42% |
| 2018 FY | 7.97 Million USD | -46.84% |
| 2018 Q4 | 7.97 Million USD | 51.91% |
| 2018 Q1 | 2.5 Million USD | -83.33% |
| 2018 Q3 | 5.24 Million USD | 109.96% |
| 2018 Q2 | 2.5 Million USD | 0.0% |
| 2017 FY | 15 Million USD | -40.0% |
| 2017 Q2 | 25 Million USD | 0.0% |
| 2017 Q3 | 27.6 Million USD | 10.4% |
| 2017 Q1 | 25 Million USD | 0.0% |
| 2017 Q4 | 15 Million USD | -45.65% |
| 2016 Q4 | 25 Million USD | 0.0% |
| 2016 Q2 | 25 Million USD | 0.0% |
| 2016 Q3 | 25 Million USD | 0.0% |
| 2016 Q1 | 25 Million USD | 0.0% |
| 2016 FY | 25 Million USD | 0.0% |
| 2015 Q4 | 25 Million USD | 0.0% |
| 2015 Q3 | 25 Million USD | 16.43% |
| 2015 Q2 | 21.47 Million USD | 2.74% |
| 2015 Q1 | 20.89 Million USD | 2.63% |
| 2015 FY | 25 Million USD | 22.77% |
| 2014 Q3 | 19.85 Million USD | 2.5% |
| 2014 Q2 | 19.36 Million USD | 2.38% |
| 2014 Q1 | 18.91 Million USD | 2.27% |
| 2014 FY | 20.36 Million USD | 10.1% |
| 2014 Q4 | 20.36 Million USD | 2.58% |
| 2013 Q2 | 6.38 Million USD | 1.58% |
| 2013 FY | 18.49 Million USD | 2702.42% |
| 2013 Q4 | 18.49 Million USD | 185.12% |
| 2013 Q3 | 6.48 Million USD | 1.66% |
| 2013 Q1 | 6.28 Million USD | 851.82% |
| 2012 Q1 | 975 Thousand USD | 233.9% |
| 2012 FY | 660 Thousand USD | -32.72% |
| 2012 Q4 | 660 Thousand USD | -27.07% |
| 2012 Q3 | 905 Thousand USD | -3.62% |
| 2012 Q2 | 939 Thousand USD | -3.69% |
| 2011 Q2 | 1.06 Million USD | -4.67% |
| 2011 FY | 981 Thousand USD | -8.4% |
| 2011 Q4 | 292 Thousand USD | -71.0% |
| 2011 Q3 | 1 Million USD | -5.09% |
| 2011 Q1 | 1.11 Million USD | 154.69% |
| 2010 Q2 | 5.35 Million USD | -55.74% |
| 2010 FY | 1.07 Million USD | -90.68% |
| 2010 Q3 | 524 Thousand USD | -90.21% |
| 2010 Q4 | 437 Thousand USD | -16.6% |
| 2010 Q1 | 12.09 Million USD | 5.3% |
| 2009 FY | 11.48 Million USD | 13.41% |
| 2009 Q4 | 11.48 Million USD | -6.67% |
| 2009 Q1 | 12.91 Million USD | -5.45% |
| 2009 Q2 | 10.29 Million USD | -20.33% |
| 2009 Q3 | 12.3 Million USD | 19.59% |
| 2008 Q3 | 14.36 Million USD | 45.02% |
| 2008 Q4 | 13.66 Million USD | -4.87% |
| 2008 Q2 | 9.9 Million USD | -33.8% |
| 2008 Q1 | 14.95 Million USD | -1.9% |
| 2008 FY | 10.12 Million USD | -33.58% |
| 2007 Q3 | 14.36 Million USD | 6.31% |
| 2007 FY | 15.24 Million USD | 12.05% |
| 2007 Q1 | 13.29 Million USD | -2.31% |
| 2007 Q2 | 13.51 Million USD | 1.65% |
| 2007 Q4 | 15.24 Million USD | 6.15% |
| 2006 Q1 | 13.2 Million USD | 170.01% |
| 2006 Q4 | 13.6 Million USD | 2.41% |
| 2006 Q3 | 13.28 Million USD | -2.75% |
| 2006 Q2 | 13.66 Million USD | 3.48% |
| 2006 FY | 13.6 Million USD | 178.25% |
| 2005 Q4 | 4.89 Million USD | -55.92% |
| 2005 Q3 | 11.09 Million USD | 0.74% |
| 2005 Q2 | 11.01 Million USD | -0.13% |
| 2005 Q1 | 11.02 Million USD | 45.43% |
| 2005 FY | 4.89 Million USD | -35.5% |
| 2004 Q4 | 7.58 Million USD | -1.01% |
| 2004 Q3 | 7.66 Million USD | 338.72% |
| 2004 Q2 | 1.74 Million USD | 36.41% |
| 2004 Q1 | 1.28 Million USD | 17.0% |
| 2004 FY | 7.58 Million USD | 593.14% |
| 2003 Q1 | 586 Thousand USD | 31.69% |
| 2003 FY | 1.09 Million USD | 145.84% |
| 2003 Q4 | 1.09 Million USD | 37.26% |
| 2003 Q3 | 797 Thousand USD | 52.68% |
| 2003 Q2 | 522 Thousand USD | -10.92% |
| 2002 Q4 | 445 Thousand USD | -69.1% |
| 2002 FY | 445 Thousand USD | 477.92% |
| 2002 Q1 | 66 Thousand USD | -14.29% |
| 2002 Q2 | 55 Thousand USD | -16.67% |
| 2002 Q3 | 1.44 Million USD | 2518.18% |
| 2001 Q4 | 77 Thousand USD | 120.0% |
| 2001 Q3 | 35 Thousand USD | -10.26% |
| 2001 FY | 77 Thousand USD | 60.42% |
| 2001 Q1 | 42 Thousand USD | -12.5% |
| 2001 Q2 | 39 Thousand USD | -7.14% |
| 2000 FY | 48 Thousand USD | 0.0% |
| 2000 Q3 | 51 Thousand USD | -7.27% |
| 2000 Q1 | 59 Thousand USD | 22.92% |
| 2000 Q2 | 55 Thousand USD | -6.78% |
| 2000 Q4 | 48 Thousand USD | -5.88% |
| 1999 Q4 | 48 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | 48 Thousand USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q2 | 1.2 Million USD | 9.09% |
| 1997 FY | - USD | -100.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q1 | 1.1 Million USD | 1000.0% |
| 1997 Q3 | 1 Million USD | -16.67% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1996 Q4 | 100 Thousand USD | 0.0% |
| 1996 Q3 | - USD | -100.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 2.8 Million USD | 75.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 Q1 | 1.6 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | 142 Thousand USD | -11752.113% |
| Psyence Biomedical Ltd. | 7.65 Million USD | -119.787% |
| XOMA Corporation | 124.45 Million USD | 86.476% |
| Mesoblast Limited | 118.92 Million USD | 85.848% |
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 92.657% |
| Aptorum Group Limited | 3.36 Million USD | -400.536% |
| Qualigen Therapeutics, Inc. | 1.29 Million USD | -1195.397% |
| HilleVax, Inc. | 51.19 Million USD | 67.124% |
| Rocket Pharmaceuticals, Inc. | 25.04 Million USD | 32.793% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 19.413% |
| Precision BioSciences, Inc. | 31.26 Million USD | 46.175% |
| Dyadic International, Inc. | 136.92 Thousand USD | -12191.041% |
| Intensity Therapeutics, Inc. | 158 Thousand USD | -10551.899% |
| IDEAYA Biosciences, Inc. | 2.87 Million USD | -486.003% |
| Eton Pharmaceuticals, Inc. | 5.45 Million USD | -208.524% |
| VYNE Therapeutics Inc. | 214 Thousand USD | -7764.486% |
| EyePoint Pharmaceuticals, Inc. | 5.46 Million USD | -207.735% |
| Adaptive Biotechnologies Corporation | 229.43 Million USD | 92.664% |
| Tenaya Therapeutics, Inc. | 12.42 Million USD | -35.464% |
| IGM Biosciences, Inc. | 40.5 Million USD | 58.451% |
| Opthea Limited | 200.62 Million USD | 91.611% |
| Milestone Pharmaceuticals Inc. | 51.77 Million USD | 67.494% |
| Abeona Therapeutics Inc. | 5.4 Million USD | -211.667% |
| Tonix Pharmaceuticals Holding Corp. | 9.81 Million USD | -71.507% |
| Ligand Pharmaceuticals Incorporated | 6.16 Million USD | -172.993% |
| NextCure, Inc. | 6.6 Million USD | -154.807% |
| Inhibikase Therapeutics, Inc. | 622 Thousand USD | -2605.775% |
| Ovid Therapeutics Inc. | 46 Million USD | 63.414% |
| CASI Pharmaceuticals, Inc. | 21.23 Million USD | 20.759% |
| Arcturus Therapeutics Holdings Inc. | 30.21 Million USD | 44.301% |
| Syros Pharmaceuticals, Inc. | 62.07 Million USD | 72.888% |
| Senti Biosciences, Inc. | 37.66 Million USD | 55.318% |
| Apollomics, Inc. | 4.66 Million USD | -261.081% |
| PureTech Health plc | 25.51 Million USD | 34.031% |
| Oncternal Therapeutics, Inc. | 318 Thousand USD | -5192.453% |
| Barinthus Biotherapeutics plc | 12.97 Million USD | -29.701% |
| Kymera Therapeutics, Inc. | 84.67 Million USD | 80.124% |
| ChromaDex Corporation | 3.27 Million USD | -413.579% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 104.18 Million USD | 83.846% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 55.831% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 104.77 Million USD | 83.937% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | 103.53 Million USD | 83.745% |
| BioXcel Therapeutics, Inc. | 101.38 Million USD | 83.4% |
| Fortress Biotech, Inc. | 88.59 Million USD | 81.003% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 63.16 Million USD | 73.356% |
| Celcuity Inc. | 37.44 Million USD | 55.056% |
| ContextLogic Inc. | 6 Million USD | -180.5% |
| GH Research PLC | 343 Thousand USD | -4806.706% |
| HOOKIPA Pharma Inc. | 6.55 Million USD | -156.594% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -45386.486% |
| ImmuCell Corporation | 11.96 Million USD | -40.61% |
| Amarin Corporation plc | 8.73 Million USD | -92.629% |
| TG Therapeutics, Inc. | 110.79 Million USD | 84.81% |
| X4 Pharmaceuticals, Inc. | 58.28 Million USD | 71.123% |
| Acelyrin, Inc. | 1.19 Million USD | -1309.548% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Seer, Inc. | 28.25 Million USD | 40.444% |
| Novavax, Inc. | 280.63 Million USD | 94.003% |
| Phathom Pharmaceuticals, Inc. | 139.03 Million USD | 87.895% |
| Jazz Pharmaceuticals plc | 5.79 Billion USD | 99.71% |
| AnaptysBio, Inc. | 17.81 Million USD | 5.524% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | -211.84% |
| PMV Pharmaceuticals, Inc. | 13.28 Million USD | -26.675% |
| AbCellera Biologics Inc. | 77.38 Million USD | 78.25% |
| CorMedix Inc. | 667.63 Thousand USD | -2420.85% |
| Cartesian Therapeutics, Inc. | 10.95 Million USD | -53.628% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.377% |
| Aptose Biosciences Inc. | 1 Million USD | -1566.657% |
| ZyVersa Therapeutics, Inc. | 8656.00 USD | -194331.608% |
| Soligenix, Inc. | 3.49 Million USD | -381.606% |
| Century Therapeutics, Inc. | 48.17 Million USD | 65.062% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | 85.387% |
| TransCode Therapeutics, Inc. | 450.57 Thousand USD | -3635.26% |
| Kura Oncology, Inc. | 17.2 Million USD | 2.151% |
| RAPT Therapeutics, Inc. | 6.9 Million USD | -143.701% |
| Ardelyx, Inc. | 55.98 Million USD | 69.937% |
| Ainos, Inc. | 5.96 Million USD | -182.214% |
| TScan Therapeutics, Inc. | 92.43 Million USD | 81.792% |
| Ocean Biomedical, Inc. | 2.15 Million USD | -682.791% |
| Prothena Corporation plc | 11.83 Million USD | -42.205% |
| CytomX Therapeutics, Inc. | 13.97 Million USD | -20.438% |
| Autolus Therapeutics plc | 52.96 Million USD | 68.225% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Adaptimmune Therapeutics plc | 25.23 Million USD | 33.307% |
| Eterna Therapeutics Inc. | 41.84 Million USD | 59.778% |
| Celularity Inc. | 65.41 Million USD | 74.273% |
| Rallybio Corporation | 392 Thousand USD | -4193.367% |
| GRI Bio, Inc. | 14 Thousand USD | -120114.286% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Omeros Corporation | 338.28 Million USD | 95.025% |
| INmune Bio, Inc. | 10.43 Million USD | -61.253% |
| Heron Therapeutics, Inc. | 179.62 Million USD | 90.631% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -184.913% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -20504.799% |
| Entero Therapeutics, Inc. | 826.84 Thousand USD | -1935.45% |
| Humacyte, Inc. | 58.1 Million USD | 71.036% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 70.919% |
| Coherus BioSciences, Inc. | 480.84 Million USD | 96.5% |
| Immunocore Holdings plc | 84.03 Million USD | 79.972% |
| Cocrystal Pharma, Inc. | 1.85 Million USD | -808.257% |
| Verastem, Inc. | 41.55 Million USD | 59.501% |
| Pliant Therapeutics, Inc. | 11.37 Million USD | -47.995% |
| Histogen Inc. | 4.62 Million USD | -264.128% |
| Surrozen, Inc. | 3.37 Million USD | -398.076% |
| Blueprint Medicines Corporation | 774.12 Million USD | 97.826% |
| Organovo Holdings, Inc. | 1.39 Million USD | -1107.317% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| IO Biotech, Inc. | 2.49 Million USD | -574.82% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| GT Biopharma, Inc. | 58 Thousand USD | -28917.241% |
| Centessa Pharmaceuticals plc | 84.58 Million USD | 80.104% |
| Hepion Pharmaceuticals, Inc. | 209.02 Thousand USD | -7951.861% |
| Cabaletta Bio, Inc. | 5.01 Million USD | -235.393% |
| Summit Therapeutics Inc. | 106.09 Million USD | 84.137% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 110.35 Million USD | 84.75% |
| BioRestorative Therapies, Inc. | 162.31 Thousand USD | -10268.6% |
| Turnstone Biologics Corp. | 3.21 Million USD | -423.647% |
| Pulmatrix, Inc. | 8.75 Million USD | -92.211% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 247 Thousand USD | -6713.765% |
| Aurinia Pharmaceuticals Inc. | 97.6 Million USD | 82.757% |
| Vigil Neuroscience, Inc. | 13.85 Million USD | -21.516% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 85.409% |
| Cytokinetics, Incorporated | 755.77 Million USD | 97.773% |
| Exelixis, Inc. | 189.94 Million USD | 91.139% |
| Nurix Therapeutics, Inc. | 30.61 Million USD | 45.025% |
| Apellis Pharmaceuticals, Inc. | 110.92 Million USD | 84.828% |
| Evogene Ltd. | 1.13 Million USD | -1378.91% |
| Replimune Group, Inc. | 75.86 Million USD | 77.817% |
| PDS Biotechnology Corporation | 23.85 Million USD | 29.439% |
| Hoth Therapeutics, Inc. | 55.16 Thousand USD | -30408.475% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -504.092% |
| ESSA Pharma Inc. | 80.32 Thousand USD | -20851.598% |
| TNF Pharmaceuticals, Inc. | 48.87 Thousand USD | -34338.306% |
| BioLineRx Ltd. | 11.59 Million USD | -45.199% |
| Avid Bioservices, Inc. | 207.83 Million USD | 91.902% |
| Insmed Incorporated | 1.2 Billion USD | 98.602% |
| VistaGen Therapeutics, Inc. | 2.12 Million USD | -693.868% |
| Zentalis Pharmaceuticals, Inc. | 45.77 Million USD | 63.232% |
| Sagimet Biosciences Inc. | 65 Thousand USD | -25792.308% |
| MediWound Ltd. | 6.71 Million USD | -150.782% |
| MiMedx Group, Inc. | 48.09 Million USD | 65.01% |
| OmniAb, Inc. | 25.56 Million USD | 34.158% |
| Alector, Inc. | 38.91 Million USD | 56.755% |
| Seres Therapeutics, Inc. | 213.93 Million USD | 92.133% |
| PTC Therapeutics, Inc. | 415.02 Million USD | 95.945% |
| Mereo BioPharma Group plc | 5.95 Million USD | -182.762% |
| Zai Lab Limited | 15.15 Million USD | -11.082% |
| Revance Therapeutics, Inc. | 478.43 Million USD | 96.482% |
| Syndax Pharmaceuticals, Inc. | 1.63 Million USD | -929.358% |
| Aura Biosciences, Inc. | 19.55 Million USD | 13.944% |
| Immunic, Inc. | 1.33 Million USD | -1161.619% |
| Dyne Therapeutics, Inc. | 27.41 Million USD | 38.61% |
| Tarsus Pharmaceuticals, Inc. | 31.73 Million USD | 46.962% |
| Veracyte, Inc. | 12.63 Million USD | -33.254% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 97.39% |
| FibroGen, Inc. | 170.45 Million USD | 90.126% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -85.332% |
| Allakos Inc. | 41.46 Million USD | 59.412% |
| scPharmaceuticals Inc. | 40.26 Million USD | 58.206% |
| Fulcrum Therapeutics, Inc. | 10.82 Million USD | -55.531% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -11045.695% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | 1.63 Million USD | -930.148% |
| Sonnet BioTherapeutics Holdings, Inc. | 203.91 Thousand USD | -8153.601% |
| Amylyx Pharmaceuticals, Inc. | 4.23 Million USD | -297.215% |
| Precigen, Inc. | 7.09 Million USD | -137.142% |
| Fortrea Holdings Inc. | 1.67 Billion USD | 98.997% |
| KalVista Pharmaceuticals, Inc. | 7.31 Million USD | -130.012% |
| Incyte Corporation | 38.28 Million USD | 56.043% |
| Alzamend Neuro, Inc. | 300.71 Thousand USD | -5496.68% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 61.012% |
| XBiotech Inc. | - USD | -Infinity% |
| Aligos Therapeutics, Inc. | 11.13 Million USD | -51.104% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -504.092% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 238.63 Million USD | 92.947% |
| Akero Therapeutics, Inc. | 26.04 Million USD | 35.376% |
| Eliem Therapeutics, Inc. | 349 Thousand USD | -4722.35% |
| Lyra Therapeutics, Inc. | 26.88 Million USD | 37.391% |
| Foghorn Therapeutics Inc. | 45.07 Million USD | 62.661% |
| Agenus Inc. | 350.24 Million USD | 95.195% |
| Kiora Pharmaceuticals, Inc. | 106.89 Thousand USD | -15645.011% |
| Y-mAbs Therapeutics, Inc. | 1.41 Million USD | -1086.047% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 62.795% |
| Ultragenyx Pharmaceutical Inc. | 43.16 Million USD | 61.014% |
| Metagenomi, Inc. Common Stock | 48.22 Million USD | 65.104% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -10164.26% |
| BioCryst Pharmaceuticals, Inc. | 848.71 Million USD | 98.017% |
| UroGen Pharma Ltd. | 100.21 Million USD | 83.206% |
| Gain Therapeutics, Inc. | 1.02 Million USD | -1538.119% |
| Sutro Biopharma, Inc. | 182.74 Million USD | 90.791% |
| Creative Medical Technology Holdings, Inc. | 14.19 Thousand USD | -118471.227% |
| Lisata Therapeutics, Inc. | 305 Thousand USD | -5418.033% |
| Chemomab Therapeutics Ltd. | 392 Thousand USD | -4193.345% |
| Stoke Therapeutics, Inc. | 6.83 Million USD | -146.233% |
| Chimerix, Inc. | 2.14 Million USD | -684.981% |
| Reneo Pharmaceuticals, Inc. | 973 Thousand USD | -1629.702% |
| Outlook Therapeutics, Inc. | 35.55 Million USD | 52.665% |
| 60 Degrees Pharmaceuticals, Inc. | 172.67 Thousand USD | -9646.747% |
| Pluri Inc. | 29.61 Million USD | 43.165% |
| Cue Biopharma, Inc. | 14.69 Million USD | -14.529% |
| MeiraGTx Holdings plc | 89.26 Million USD | 81.146% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | 21.35 Thousand USD | -78729.04% |
| Cidara Therapeutics, Inc. | 4.87 Million USD | -245.089% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Scholar Rock Holding Corporation | 61.81 Million USD | 72.775% |
| Sana Biotechnology, Inc. | 104.09 Million USD | 83.832% |
| Elicio Therapeutics, Inc. | 6.91 Million USD | -143.314% |
| NLS Pharmaceutics AG | 1.63 Million USD | -930.148% |
| Adlai Nortye Ltd. American Depositary Shares | 31.54 Million USD | 46.653% |
| Nutriband Inc. | 241.28 Thousand USD | -6875.154% |
| Protara Therapeutics, Inc. | 5.46 Million USD | -207.847% |
| Vor Biopharma Inc. | 35.66 Million USD | 52.804% |
| Roivant Sciences Ltd. | 499.74 Million USD | 96.632% |
| ProKidney Corp. | 4.41 Million USD | -281.373% |
| Applied Therapeutics, Inc. | 1.22 Million USD | -1272.757% |
| Daré Bioscience, Inc. | 5.31 Million USD | -216.464% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.033% |
| Titan Pharmaceuticals, Inc. | 565 Thousand USD | -2878.761% |
| Bicycle Therapeutics plc | 44.95 Million USD | 62.563% |
| Tango Therapeutics, Inc. | 38.92 Million USD | 56.757% |
| Galectin Therapeutics Inc. | 71.8 Million USD | 76.562% |
| Revolution Medicines, Inc. Warrant | 87.94 Million USD | 80.863% |
| Atai Life Sciences N.V. | 16.47 Million USD | -2.149% |
| Renovaro Biosciences Inc. | 2.45 Million USD | -586.66% |
| Aerovate Therapeutics, Inc. | 675 Thousand USD | -2393.333% |
| MediciNova, Inc. | 215.92 Thousand USD | -7694.337% |
| Praxis Precision Medicines, Inc. | 2.49 Million USD | -574.549% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -1234.625% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Protagonist Therapeutics, Inc. | 1.14 Million USD | -1375.022% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 90.97% |
| Biomea Fusion, Inc. | 10.29 Million USD | -63.462% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 55.85 Million USD | 69.871% |
| Cullinan Oncology, Inc. | 3.59 Million USD | -368.802% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -83.714% |
| 4D Molecular Therapeutics, Inc. | 14.67 Million USD | -14.716% |
| Kiniksa Pharmaceuticals, Ltd. | 12.25 Million USD | -37.298% |
| bluebird bio, Inc. | 330.32 Million USD | 94.905% |
| Ventyx Biosciences, Inc. | 12.5 Million USD | -34.575% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Imunon, Inc. | 1.62 Million USD | -935.875% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 98.516% |
| BioAtla, Inc. | 2.46 Million USD | -584.146% |
| Allogene Therapeutics, Inc. | 95.12 Million USD | 82.307% |
| Larimar Therapeutics, Inc. | 5.54 Million USD | -203.462% |
| DBV Technologies S.A. | 14.38 Million USD | -17.029% |
| Fortress Biotech, Inc. | 88.59 Million USD | 81.003% |
| Avidity Biosciences, Inc. | 9.85 Million USD | -70.828% |
| Kezar Life Sciences, Inc. | 18.93 Million USD | 11.108% |
| aTyr Pharma, Inc. | 15.09 Million USD | -11.494% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | 20.04% |
| EyeGate Pharmaceuticals, Inc. | 326.49 Thousand USD | -5054.781% |
| Galecto, Inc. | 249 Thousand USD | -6659.036% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -931.424% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.877% |
| Lexicon Pharmaceuticals, Inc. | 106.06 Million USD | 84.132% |
| Entera Bio Ltd. | 390 Thousand USD | -4215.385% |
| Travere Therapeutics, Inc. | 404.78 Million USD | 95.842% |
| Sensei Biotherapeutics, Inc. | 6.2 Million USD | -171.102% |
| Xencor, Inc. | 83.43 Million USD | 79.828% |
| Orchestra BioMed Holdings, Inc. | 1.68 Million USD | -897.629% |
| Spruce Biosciences, Inc. | 4.6 Million USD | -265.155% |
| Coeptis Therapeutics Holdings, Inc. | 1.22 Million USD | -1274.746% |
| Vanda Pharmaceuticals Inc. | 9.4 Million USD | -78.966% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -10164.26% |
| Portage Biotech Inc. | 47 Thousand USD | -35708.511% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -1234.625% |
| Olema Pharmaceuticals, Inc. | 2.41 Million USD | -596.318% |
| OncoCyte Corporation | 2.86 Million USD | -486.616% |
| Processa Pharmaceuticals, Inc. | 150.55 Thousand USD | -11078.713% |
| Purple Biotech Ltd. | 351 Thousand USD | -4694.872% |
| CollPlant Biotechnologies Ltd. | 3.15 Million USD | -432.764% |
| Onconetix, Inc. | 9.88 Million USD | -70.245% |
| MacroGenics, Inc. | 33.97 Million USD | 50.458% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | 2.03 Million USD | -727.434% |
| Neumora Therapeutics, Inc. Common Stock | 5.23 Million USD | -221.736% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | 13.63 Million USD | -23.45% |
| Aditxt, Inc. | 18.21 Million USD | 7.619% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.73 Million USD | 37.056% |
| Curis, Inc. | 2.79 Million USD | -502.362% |
| Carmell Therapeutics Corporation | 2.13 Million USD | -687.756% |
| Adagene Inc. | 22.3 Million USD | 24.552% |
| Achieve Life Sciences, Inc. | 16.73 Million USD | -0.592% |
| BeiGene, Ltd. | 930.18 Million USD | 98.191% |
| Inhibrx Biosciences, Inc. | 210.14 Million USD | 91.991% |
| GlycoMimetics, Inc. | 808.4 Thousand USD | -1981.885% |
| Maravai LifeSciences Holdings, Inc. | 610.96 Million USD | 97.245% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| SciSparc Ltd. | 76 Thousand USD | -22044.737% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 2.5 Million USD | -572.662% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 79.48% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 205.91 Million USD | 91.827% |
| Acrivon Therapeutics, Inc. Common Stock | 4.64 Million USD | -262.403% |
| Alnylam Pharmaceuticals, Inc. | 2.68 Billion USD | 99.373% |
| ADMA Biologics, Inc. | 141.41 Million USD | 88.099% |
| Rigel Pharmaceuticals, Inc. | 60.57 Million USD | 72.218% |
| Clene Inc. | 32.16 Million USD | 47.67% |
| Celldex Therapeutics, Inc. | 2.54 Million USD | -562.077% |
| Cogent Biosciences, Inc. | 18.85 Million USD | 10.73% |
| Boundless Bio, Inc. Common Stock | 2.19 Million USD | -666.743% |
| Recursion Pharmaceuticals, Inc. | 50.67 Million USD | 66.786% |
| Adicet Bio, Inc. | 20.92 Million USD | 19.566% |
| Contineum Therapeutics, Inc. Class A Common Stock | 193.19 Million USD | 91.288% |
| Absci Corporation | 15.95 Million USD | -5.471% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 15.3 Million USD | -9.978% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 20.29 Million USD | 17.065% |
| Surrozen, Inc. | 3.37 Million USD | -398.076% |
| Generation Bio Co. | 97.89 Million USD | 82.808% |
| Astria Therapeutics, Inc. | 329 Thousand USD | -5015.502% |
| Caribou Biosciences, Inc. | 27.48 Million USD | 38.767% |
| Black Diamond Therapeutics, Inc. | 25.29 Million USD | 33.473% |
| Janux Therapeutics, Inc. | 24.54 Million USD | 31.424% |
| Invivyd, Inc. | 2.16 Million USD | -677.367% |
| Cingulate Inc. | 3.13 Million USD | -436.825% |
| Relay Therapeutics, Inc. | 53.46 Million USD | 68.522% |
| Quoin Pharmaceuticals, Ltd. | 3523.73 USD | -477518.887% |
| Tenax Therapeutics, Inc. | 500.9 Thousand USD | -3259.932% |
| Spero Therapeutics, Inc. | 5.54 Million USD | -203.626% |
| Jaguar Health, Inc. | 35.86 Million USD | 53.067% |
| Artelo Biosciences, Inc. | 63 Thousand USD | -26614.286% |
| 2seventy bio, Inc. | 256.67 Million USD | 93.443% |
| Clearside Biomedical, Inc. | 43 Million USD | 60.861% |
| Terns Pharmaceuticals, Inc. | 603 Thousand USD | -2691.045% |
| ACADIA Pharmaceuticals Inc. | 57.2 Million USD | 70.579% |
| Capricor Therapeutics, Inc. | 5.61 Million USD | -199.885% |
| Citius Pharmaceuticals, Inc. | 481.24 Thousand USD | -3397.179% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 28.27 Million USD | 40.471% |
| Innoviva, Inc. | 449.07 Million USD | 96.252% |
| Bolt Biotherapeutics, Inc. | 20.21 Million USD | 16.761% |
| Entrada Therapeutics, Inc. | 68.23 Million USD | 75.333% |
| ALX Oncology Holdings Inc. | 17.19 Million USD | 2.134% |
| Vir Biotechnology, Inc. | 124.54 Million USD | 86.486% |
| Evaxion Biotech A/S | 10.86 Million USD | -54.834% |
| Ocular Therapeutix, Inc. | 83.38 Million USD | 79.817% |
| Verve Therapeutics, Inc. | 74.9 Million USD | 77.532% |
| Tyra Biosciences, Inc. | 6.49 Million USD | -159.083% |
| Galmed Pharmaceuticals Ltd. | 41 Thousand USD | -40948.78% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 37.644% |
| Connect Biopharma Holdings Limited | 465 Thousand USD | -3519.355% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| AlloVir, Inc. | 27.42 Million USD | 38.642% |
| ORIC Pharmaceuticals, Inc. | 10.21 Million USD | -64.79% |
| Catalyst Pharmaceuticals, Inc. | 3.55 Million USD | -373.152% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -982.315% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -1235.714% |
| Keros Therapeutics, Inc. | 14.44 Million USD | -16.519% |
| SELLAS Life Sciences Group, Inc. | 906 Thousand USD | -1757.616% |
| Crinetics Pharmaceuticals, Inc. | 51.72 Million USD | 67.464% |
| ImmunityBio, Inc. | 883.67 Million USD | 98.095% |
| Korro Bio, Inc. | 33.2 Million USD | 49.318% |
| C4 Therapeutics, Inc. | 70.97 Million USD | 76.288% |
| Kineta, Inc. | 1.31 Million USD | -1177.904% |
| Lantern Pharma Inc. | 234.47 Thousand USD | -7077.86% |
| BioVie Inc. | 6.11 Million USD | -175.385% |
| Codexis, Inc. | 22.36 Million USD | 24.745% |
| Celularity Inc. | 65.41 Million USD | 74.273% |
| Eledon Pharmaceuticals, Inc. | 383 Thousand USD | -4294.256% |
| Virax Biolabs Group Limited | 224.3 Thousand USD | -7403.344% |
| Kodiak Sciences Inc. | 181.63 Million USD | 90.734% |
| Cibus, Inc. | 24.62 Million USD | 31.644% |
| Annexon, Inc. | 31.35 Million USD | 46.324% |
| Assembly Biosciences, Inc. | 2.34 Million USD | -618.617% |
| Moderna, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.842% |
| Adverum Biotechnologies, Inc. | 75.03 Million USD | 77.571% |
| Avalo Therapeutics, Inc. | 3.9 Million USD | -331.207% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Eyenovia, Inc. | 16.1 Million USD | -4.484% |
| Puma Biotechnology, Inc. | 111.49 Million USD | 84.904% |
| Monte Rosa Therapeutics, Inc. | 46.03 Million USD | 63.444% |
| Wave Life Sciences Ltd. | 32.11 Million USD | 47.599% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -1608.629% |
| Xilio Therapeutics, Inc. | 11.45 Million USD | -46.897% |
| Alkermes plc | 290.73 Million USD | 94.211% |
| Arcellx, Inc. | 97.62 Million USD | 82.761% |
| Moolec Science SA | 2.64 Million USD | -536.225% |
| Cardiff Oncology, Inc. | 2.14 Million USD | -683.155% |
| LAVA Therapeutics N.V. | 6.31 Million USD | -166.593% |
| Enanta Pharmaceuticals, Inc. | 26.51 Million USD | 36.522% |
| Regulus Therapeutics Inc. | 3.1 Million USD | -442.553% |
| Atea Pharmaceuticals, Inc. | 2.4 Million USD | -600.666% |
| Compass Therapeutics, Inc. | 1.73 Million USD | -871.148% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| Humacyte, Inc. | 58.1 Million USD | 71.036% |
| Acumen Pharmaceuticals, Inc. | 28.48 Million USD | 40.92% |
| Geron Corporation | 85.89 Million USD | 80.407% |
| Verrica Pharmaceuticals Inc. | 45.51 Million USD | 63.019% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Royalty Pharma plc | 6.13 Billion USD | 99.726% |
| TFF Pharmaceuticals, Inc. | 115.25 Thousand USD | -14502.53% |
| Notable Labs, Ltd. | 2.04 Million USD | -721.376% |
| Mersana Therapeutics, Inc. | 33.83 Million USD | 50.251% |
| Structure Therapeutics Inc. | 5.45 Million USD | -208.637% |
| IN8bio, Inc. | 4.89 Million USD | -243.961% |
| 89bio, Inc. | 27.1 Million USD | 37.915% |
| DiaMedica Therapeutics Inc. | 400 Thousand USD | -4107.5% |
| Vera Therapeutics, Inc. | 53.7 Million USD | 68.664% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| Genelux Corporation | 2.51 Million USD | -568.122% |
| Trevi Therapeutics, Inc. | 1.33 Million USD | -1157.848% |
| Liquidia Corporation | 3.5 Million USD | -380.445% |
| Mustang Bio, Inc. | 2.49 Million USD | -573.739% |
| Immunovant, Inc. | 138 Thousand USD | -12095.652% |
| Vericel Corporation | 88.14 Million USD | 80.906% |
| Quantum-Si incorporated | 15.3 Million USD | -9.978% |
| Arbutus Biopharma Corporation | 8.72 Million USD | -92.982% |
| XOMA Corporation | 124.45 Million USD | 86.476% |
| ARS Pharmaceuticals, Inc. | 274 Thousand USD | -6042.336% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -20504.799% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -26.77% |
| Vaxcyte, Inc. | 29.22 Million USD | 42.41% |
| Xenon Pharmaceuticals Inc. | 10.9 Million USD | -54.361% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| NeuroBo Pharmaceuticals, Inc. | 203 Thousand USD | -8190.64% |
| Tempest Therapeutics, Inc. | 20.66 Million USD | 18.542% |
| Sol-Gel Technologies Ltd. | 1.65 Million USD | -918.149% |
| Rhythm Pharmaceuticals, Inc. | 1.26 Million USD | -1235.714% |
| Soleno Therapeutics, Inc. | 403 Thousand USD | -4076.179% |
| Enlivex Therapeutics Ltd. | 1.03 Million USD | -1530.814% |
| PepGen Inc. | 20.1 Million USD | 16.285% |
| Moleculin Biotech, Inc. | 574 Thousand USD | -2832.056% |
| United Therapeutics Corporation | 700 Million USD | 97.596% |
| Solid Biosciences Inc. | 26.26 Million USD | 35.922% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -1608.629% |
| Immuneering Corporation | 4.46 Million USD | -277.104% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | 101 Thousand USD | -16563.366% |
| Belite Bio, Inc | 886 Thousand USD | -1799.549% |
| Pharming Group N.V. | 171.54 Million USD | 90.189% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Bionomics Limited | 239.61 Million USD | 92.976% |
| Pyxis Oncology, Inc. | 21.33 Million USD | 21.101% |
| uniQure N.V. | 138.4 Million USD | 87.84% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 85.42 Million USD | 80.298% |
| Altimmune, Inc. | 671 Thousand USD | -2408.197% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -26.77% |
| Peak Bio, Inc. | 10.72 Million USD | -56.97% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -85.332% |
| FibroBiologics, Inc. Common Stock | 1.74 Million USD | -863.366% |
| Benitec Biopharma Inc. | 284 Thousand USD | -5826.056% |
| Zura Bio Limited | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 96.218% |
| Salarius Pharmaceuticals, Inc. | 289.64 Thousand USD | -5710.601% |
| Compugen Ltd. | 1.35 Million USD | -1145.744% |
| Elevai Labs, Inc. Common Stock | 210.48 Thousand USD | -7895.667% |
| argenx SE | 20 Million USD | 15.85% |
| Zevra Therapeutics, Inc. | 42.76 Million USD | 60.646% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 80.096% |
| NKGen Biotech, Inc. Common Stock | 19.92 Million USD | 15.516% |
| Madrigal Pharmaceuticals, Inc. | 117.19 Million USD | 85.639% |
| PolyPid Ltd. | 11.77 Million USD | -42.881% |
| Aileron Therapeutics, Inc. | 91.45 Million USD | 81.598% |
| Plus Therapeutics, Inc. | 4.18 Million USD | -302.535% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Dianthus Therapeutics, Inc. | 585 Thousand USD | -2776.923% |
| Instil Bio, Inc. | 86.05 Million USD | 80.443% |
| Elevation Oncology, Inc. | 30.13 Million USD | 44.155% |
| Immunome, Inc. | 1.65 Million USD | -920.0% |
| Verona Pharma plc | 51.32 Million USD | 67.212% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | 9.77 Million USD | -72.121% |
| Shattuck Labs, Inc. | 4.2 Million USD | -300.524% |
| LENZ Therapeutics, Inc. | 362 Thousand USD | -4549.171% |
| Design Therapeutics, Inc. | 3.05 Million USD | -451.803% |
| Leap Therapeutics, Inc. | 262 Thousand USD | -6323.664% |
| Seelos Therapeutics, Inc. | 14.22 Million USD | -18.288% |
| Achilles Therapeutics plc | 4.61 Million USD | -264.68% |
| Fractyl Health, Inc. Common Stock | 373.72 Million USD | 95.497% |
| Rani Therapeutics Holdings, Inc. | 30.09 Million USD | 44.085% |
| MoonLake Immunotherapeutics | 3.69 Million USD | -355.127% |
| Beam Therapeutics Inc. | 173.17 Million USD | 90.281% |
| Moolec Science SA | 2.64 Million USD | -536.225% |
| Longboard Pharmaceuticals, Inc. | 475 Thousand USD | -3443.158% |
| AEON Biopharma, Inc. | 278 Thousand USD | -5953.957% |
| Aadi Bioscience, Inc. | 7.02 Million USD | -139.607% |
| Enliven Therapeutics, Inc. | 335 Thousand USD | -4923.881% |
| Iovance Biotherapeutics, Inc. | 75.86 Million USD | 77.815% |
| Taysha Gene Therapies, Inc. | 61.1 Million USD | 72.458% |
| Inovio Pharmaceuticals, Inc. | 30.2 Million USD | 44.289% |
| Athira Pharma, Inc. | 1.58 Million USD | -961.83% |
| HCW Biologics Inc. | 6.45 Million USD | -160.858% |
| XOMA Corporation | 124.45 Million USD | 86.476% |
| NeurAxis, Inc. | 224.26 Thousand USD | -7404.682% |
| Lumos Pharma, Inc. | 6.58 Million USD | -155.581% |
| enGene Holdings Inc. Common Stock | 9.77 Million USD | -72.121% |
| 180 Life Sciences Corp. | 1.32 Million USD | -1174.933% |
| Nektar Therapeutics | 230.4 Million USD | 92.695% |
| NKGen Biotech, Inc. Warrants | 19.92 Million USD | 15.516% |
| Opiant Pharmaceuticals, Inc. | 17.08 Million USD | 1.464% |
| Arvinas, Inc. | 3.4 Million USD | -395.0% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -982.315% |
| Palisade Bio, Inc. | 369 Thousand USD | -4460.976% |
| Nutriband Inc. | 241.28 Thousand USD | -6875.154% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -931.424% |
| CG Oncology, Inc. Common stock | 826 Thousand USD | -1937.53% |
| Tourmaline Bio, Inc. | 415 Thousand USD | -3955.422% |
| Merus N.V. | 12.16 Million USD | -38.382% |
| Omega Therapeutics, Inc. | 128.42 Million USD | 86.895% |
| Neurogene Inc. | 16.25 Million USD | -3.537% |
| Mirum Pharmaceuticals, Inc. | 308.14 Million USD | 94.538% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CervoMed Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 28.54 Million USD | 41.032% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Quince Therapeutics, Inc. | 13.81 Million USD | -21.833% |
| Rezolute, Inc. | 2.22 Million USD | -655.386% |
| Clene Inc. | 32.16 Million USD | 47.67% |
| Indaptus Therapeutics, Inc. | 175.05 Thousand USD | -9514.231% |
| BeyondSpring Inc. | 3.99 Million USD | -321.277% |
| Synlogic, Inc. | 17.27 Million USD | 2.576% |
| Allarity Therapeutics, Inc. | 1.3 Million USD | -1194.615% |
| Phio Pharmaceuticals Corp. | 35 Thousand USD | -47985.714% |
| Peak Bio, Inc. | 10.72 Million USD | -56.97% |
| Werewolf Therapeutics, Inc. | 51.92 Million USD | 67.587% |
| Krystal Biotech, Inc. | 8.09 Million USD | -107.932% |
| Karyopharm Therapeutics Inc. | 177.01 Million USD | 90.492% |
| SpringWorks Therapeutics, Inc. | 7.05 Million USD | -138.487% |
| Lipella Pharmaceuticals Inc. | 136.59 Thousand USD | -12221.185% |
| MannKind Corporation | 382.37 Million USD | 95.599% |
| Ikena Oncology, Inc. | 10.73 Million USD | -56.733% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 409 Thousand USD | -4014.914% |
| Gossamer Bio, Inc. | 212.46 Million USD | 92.079% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 174 Thousand USD | -9572.414% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -83.714% |
| Legend Biotech Corporation | 328.67 Million USD | 94.879% |
| Mural Oncology plc | 15 Million USD | -12.133% |
| Disc Medicine, Inc. | 2.1 Million USD | -701.047% |
| Champions Oncology, Inc. | 7.43 Million USD | -126.514% |
| REGENXBIO Inc. | 89.29 Million USD | 81.151% |
| Ensysce Biosciences, Inc. | 854.69 Thousand USD | -1869.119% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 552.98 Thousand USD | -2943.499% |
| Edgewise Therapeutics, Inc. | 5.41 Million USD | -210.861% |
| Vaxart, Inc. | 26.51 Million USD | 36.524% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 15.65 Million USD | -7.489% |
| Cellectis S.A. | 92.85 Million USD | 81.875% |
| Longeveron Inc. | 2.04 Million USD | -724.596% |
| Repare Therapeutics Inc. | 3.41 Million USD | -393.548% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.795% |
| Inozyme Pharma, Inc. | 46.59 Million USD | 63.878% |
| Revolution Medicines, Inc. | 87.94 Million USD | 80.863% |
| Nymox Pharmaceutical Corporation | 173 Thousand USD | -9628.324% |
| Third Harmonic Bio, Inc. | 3.95 Million USD | -325.753% |
| ArriVent BioPharma, Inc. Common Stock | 317 Thousand USD | -5209.148% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 175 Thousand USD | -9517.143% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 97.918% |
| Denali Therapeutics Inc. | 52.24 Million USD | 67.784% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 14.4 Million USD | -16.831% |
| Corvus Pharmaceuticals, Inc. | 1.37 Million USD | -1124.891% |
| Cingulate Inc. | 3.13 Million USD | -436.825% |
| Passage Bio, Inc. | 26.29 Million USD | 35.993% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.66 Million USD | -152.513% |
| Day One Biopharmaceuticals, Inc. | 408 Thousand USD | -4025.0% |
| Oramed Pharmaceuticals Inc. | 894 Thousand USD | -1782.55% |
| Scinai Immunotherapeutics Ltd. | 20.56 Million USD | 18.146% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 2.45 Million USD | -586.625% |
| Carisma Therapeutics, Inc. | 3.12 Million USD | -438.905% |
| Unicycive Therapeutics, Inc. | 811 Thousand USD | -1975.216% |
| OmniAb, Inc. | 25.56 Million USD | 34.158% |
| Anew Medical, Inc. | 1.6 Million USD | -948.598% |
| Fennec Pharmaceuticals Inc. | 29.58 Million USD | 43.109% |
| Lipocine Inc. | 17.16 Thousand USD | -97942.642% |
| Lexeo Therapeutics, Inc. Common Stock | 11.63 Million USD | -44.612% |
| Nautilus Biotechnology, Inc. | 34.62 Million USD | 51.398% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -184.913% |
| G1 Therapeutics, Inc. | 57.17 Million USD | 70.563% |
| Bellerophon Therapeutics, Inc. | 203 Thousand USD | -8190.64% |
| Sage Therapeutics, Inc. | 5.16 Million USD | -225.847% |
| Ocugen, Inc. | 6.94 Million USD | -142.472% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | -19.117% |
| Q32 Bio Inc. | 1.31 Million USD | -1176.935% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | -2404.464% |
| Alumis Inc. Common Stock | 32.58 Million USD | 48.343% |
| Equillium, Inc. | 824 Thousand USD | -1942.476% |
| Kyverna Therapeutics, Inc. | 9.07 Million USD | -85.373% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | 300.8 Thousand USD | -5494.968% |
| Dominari Holdings Inc. | 3.02 Million USD | -455.812% |
| Edesa Biotech, Inc. | 94.48 Thousand USD | -17711.974% |
| vTv Therapeutics Inc. | 529 Thousand USD | -3081.474% |
| Bio-Techne Corporation | 419.53 Million USD | 95.988% |
| Agios Pharmaceuticals, Inc. | 71.99 Million USD | 76.624% |
| Harmony Biosciences Holdings, Inc. | 193.56 Million USD | 91.305% |
| Prelude Therapeutics Incorporated | 16.88 Million USD | 0.343% |
| Candel Therapeutics, Inc. | 22.76 Million USD | 26.061% |
| iTeos Therapeutics, Inc. | 6.05 Million USD | -177.814% |
| Nkarta, Inc. | 88.33 Million USD | 80.948% |
| BioCardia, Inc. | 1.31 Million USD | -1179.848% |
| Iterum Therapeutics plc | 19.5 Million USD | 13.732% |